Calyx Supply Simulation Service Launched
Service uses simulation modeling methodology to evaluate the quantity of medication produced for use in clinical development.
E-Clinical and Regulatory solutions and services provider Calyx has announced its Calyx Supply Simulation clinical trial supply forecasting service. Available through the company’s in-house statistical design and trial supplies consultants, the service uses simulation modeling methodology and over 50 design parameters that closely mimic an Interactive Response Technology (IRT) system, to evaluate the quantity of medication produced for use in clinical development.
By providing better-aligned medication scenarios—for trial start-up and continued enrollment, how long an existing amount of study medication will last and determining optimal site and depot buffer stock quantities—can help sponsors reduce cost and excessive drug wastage.
Reference: Calyx Launches Supply Simulation Service to Forecast and Optimize Clinical Trial Supplies; Nottingham, England and Morrisville, NC. March 7, 2023
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
